Presentation is loading. Please wait.

Presentation is loading. Please wait.

La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona

Similar presentations


Presentation on theme: "La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona"— Presentation transcript:

1 La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona
Lab Nanobioingeniería (IBEC) Coordinador Plataforma Española de Nanomedicina Director Adjunto CIBER BBN

2 Informe FENIN 2006 Biotecnologia

3 Técnicas clásicas (Macro)
Nuevas Tecnologías Miniaturización Técnicas clásicas (Macro) Microdispositivos Nanotecnología Convergencia de tecnologías Richard Feynman

4

5 Given Imaging Ltd Comercial

6 Definition: NanoMedicine, for the purpose of this vision document, is defined as the application of Nanotechnology to Health. It exploits the improved and often novel physical, chemical, and biological properties of materials at the nanometric scale. NanoMedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases.

7 Entorn internacional NIH Nanomedicine Roadmap Initiative, emprendida por el Instituto Nacional de Salud de EE.UU en mayo de 2004 (http://www.capconcorp.com/roadmap04/) ESF Scientific Forward Look on Nanomedicine, presentado por el comité de expertos de la European Science Foundation en febrero de 2005 (http://www.esf.org/newsrelease/83/SPB23Nanomedicine.pdf) EuroNanoForum 2005, Nanotechnology and the Health of the EU Citizen in 2020 (Edimburgo, 6 – 9 septiembre de 2005).

8 Overview of main recommendations

9 (2006)

10 PRESENTACIÓN DEL INFORME PLATAFORMA ESPAÑOLA DE NANOMEDICINA

11 PLATAFORMA ESPAÑOLA DE NANOMEDICINA
Jornadas de Plataformas Tecnológicas Josep Samitier Parc Científic de Barcelona-Univ. de Barcelona Institut de Bioenginyeria de Catalunya (IBEC)

12 MIEMBROS 108 grupos diferentes

13 GRUPOS DE TRABAJO Nanodiagnóstico Medicina Regenerativa
Liberación de Fármacos Educación / Comunicación Toxicidad / Regulación

14 MIEMBROS Por Comunidades Autónomas

15 EURONANOBIO WP1 Experts Workshop
Nanobio Clusters: identifying best practices Dr Arantxa Sanz Prof. Josep Samitier Institute for Bioengineering of Catalonia (IBEC) Barcelona, SPAIN

16 WP1:OBJECTIVES AND METHOD
GLOBAL OBJECTIVE: Identifying best practices across the most successful clusters As integration is key to success in nanobio, success = high quality, common research projects and results (with diverse cluster members as partners) DATA COLLECTION and ANALYSIS: METHODOLOGY (Feb-May 09) Definition of a nanobio cluster in the study: research vs innovation cluster Mapping clusters elsewhere: USA, Canada, Asia-Pacific Mapping clusters in Europe Identifying best practices via SWOT analysis Consolidation workshop: discussion and brainstorming Be careful with the use of “cluster” for both, one given the “aggregate” nature of the nanobio research institution/entity, the other one because it is the conventional meaning for cluster (involving industry, innovation, market, clinical transfer) Size: One, two nodes, approx. 100kms away max.

17 USA: mapping preliminary results
BAY AREA SOUTH CALIFORNIA HOUSTON CHICAGO BOSTON CORNELL N. CAROLINA Research Clinical Cluster agency Innovation Cluster agency non specific Be careful with the use of “cluster” for both, one given the “aggregate” nature of the nanobio research institution/entity, the other one because it is the conventional meaning for cluster (involving industry, innovation, market, clinical transfer) Size: One, two nodes, approx. 100kms away max.

18 ASIA PACIFIC – preliminary results
TSUKUBA / TOKYO KOBE YONSEI (SEOUL) SINGAPORE SIDNEY … Research Clinical Cluster agency Innovation Cluster agency non specific Be careful with the use of “cluster” for both, one given the “aggregate” nature of the nanobio research institution/entity, the other one because it is the conventional meaning for cluster (involving industry, innovation, market, clinical transfer) Size: One, two nodes, approx. 100kms away max.

19 European Union: mapping preliminary results
Most advanced nanobio clusters across EU + associate states: -Higher integration level of actors, including hospitals -Remarkable common output in terms of funded projects, research papers and patents / creation of spin off companies Research Clinical Cluster agency Innovation Cluster agency non specific Most advanced: higher degree of integration at academia-hospital-industry activities,

20 HOUSTON STRENGTHS WEAKNESSES OPPORTUNITIES THREATS
SWOT analysis: Applying criteria for case studies HOUSTON STRENGTHS First-class medical research Materials science tradition and expertise from oil industry University of Texas system Clinical transfer WEAKNESSES Number of spin off companies/ Innovation levels: not as high as they might be (compared to California, Massachussets, Chicago) OPPORTUNITIES Alliance for Nanohealth NIH programme. Purdue Centre of Excellence THREATS Very specialized on cancer but it cannot be the only one – see the distributed NIH network Health system ??? Connected = networks, virtual institutes, common projects, training / education programmes…

21 MÜNSTER – EXAMPLE STRENGTHS WEAKNESSES OPPORTUNITIES THREATENS
SWOT analysis for the mapped clusters (some examples…) MÜNSTER – EXAMPLE STRENGTHS BioAnalytik Munster: Facilitator, coordinator Integration of excellent academic and clinical research Good levels of partnership with industry: Tradition in instrumentation Innovation/ Tech transfer: nanobio start ups WEAKNESSES Talent attraction : not a capital city OPPORTUNITIES Very strong support from local government (Munster City council): Branding Social capital: easy to network and meet THREATENS National support: Other competitive German clusters Connected = networks, virtual institutes, common projects, training / education programmes…

22


Download ppt "La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona"

Similar presentations


Ads by Google